187 related articles for article (PubMed ID: 25742740)
1. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
Farra R; Dapas B; Baiz D; Tonon F; Chiaretti S; Del Sal G; Rustighi A; Elvassore N; Pozzato G; Grassi M; Grassi G
Biochimie; 2015 May; 112():85-95. PubMed ID: 25742740
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
Baiz D; Dapas B; Farra R; Scaggiante B; Pozzato G; Zanconati F; Fiotti N; Consoloni L; Chiaretti S; Grassi G
World J Gastroenterol; 2014 Jan; 20(3):795-803. PubMed ID: 24574752
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
[TBL] [Abstract][Full Text] [Related]
4. Expression and significance of Pin1, β-catenin and cyclin D1 in hepatocellular carcinoma.
Ao R; Zhang DR; Du YQ; Wang Y
Mol Med Rep; 2014 Oct; 10(4):1893-8. PubMed ID: 25109821
[TBL] [Abstract][Full Text] [Related]
5. Effects of E2F1-cyclin E1-E2 circuit down regulation in hepatocellular carcinoma cells.
Farra R; Dapas B; Pozzato G; Scaggiante B; Agostini F; Zennaro C; Grassi M; Rosso N; Giansante C; Fiotti N; Grassi G
Dig Liver Dis; 2011 Dec; 43(12):1006-14. PubMed ID: 21831731
[TBL] [Abstract][Full Text] [Related]
6. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis.
Pang R; Lee TK; Poon RT; Fan ST; Wong KB; Kwong YL; Tse E
Gastroenterology; 2007 Mar; 132(3):1088-103. PubMed ID: 17383430
[TBL] [Abstract][Full Text] [Related]
7. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
8. Understanding the role of PIN1 in hepatocellular carcinoma.
Cheng CW; Leong KW; Tse E
World J Gastroenterol; 2016 Dec; 22(45):9921-9932. PubMed ID: 28018099
[TBL] [Abstract][Full Text] [Related]
9. PIN1 expression contributes to hepatic carcinogenesis.
Pang RW; Lee TK; Man K; Poon RT; Fan ST; Kwong YL; Tse E
J Pathol; 2006 Sep; 210(1):19-25. PubMed ID: 16841372
[TBL] [Abstract][Full Text] [Related]
10. Pin1 facilitates NF-κB activation and promotes tumour progression in human hepatocellular carcinoma.
Shinoda K; Kuboki S; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Miyazaki M
Br J Cancer; 2015 Nov; 113(9):1323-31. PubMed ID: 26461058
[TBL] [Abstract][Full Text] [Related]
11. PIN1 in hepatocellular carcinoma is associated with TP53 gene status.
Bae JS; Noh SJ; Kim KM; Jang KY; Park HS; Chung MJ; Park BH; Moon WS
Oncol Rep; 2016 Oct; 36(4):2405-11. PubMed ID: 27499097
[TBL] [Abstract][Full Text] [Related]
12. Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways.
Liao XH; Zhang AL; Zheng M; Li MQ; Chen CP; Xu H; Chu QS; Yang D; Lu W; Tsai TF; Liu H; Zhou XZ; Lu KP
Sci Rep; 2017 Mar; 7():43639. PubMed ID: 28262728
[TBL] [Abstract][Full Text] [Related]
13. Pin1 acts as a modulator of cell proliferation through alteration in NF-κB but not β-catenin/TCF4 signalling in a subset of endometrial carcinoma cells.
Saegusa M; Hashimura M; Kuwata T
J Pathol; 2010 Dec; 222(4):410-20. PubMed ID: 20922712
[TBL] [Abstract][Full Text] [Related]
14. PIN1 gene overexpression and beta-catenin gene mutation/expression in hepatocellular carcinoma and their significance.
Wang H; Zhang J; Feng W; Zhang S; Liang H; Wang Y; Zheng Q; Li Z
J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):54-7. PubMed ID: 17393110
[TBL] [Abstract][Full Text] [Related]
15. Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development.
Pu W; Li J; Zheng Y; Shen X; Fan X; Zhou JK; He J; Deng Y; Liu X; Wang C; Yang S; Chen Q; Liu L; Zhang G; Wei YQ; Peng Y
Hepatology; 2018 Aug; 68(2):547-560. PubMed ID: 29381806
[TBL] [Abstract][Full Text] [Related]
16. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation.
Lee NY; Choi HK; Shim JH; Kang KW; Dong Z; Choi HS
Carcinogenesis; 2009 Apr; 30(4):671-81. PubMed ID: 19168580
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma.
Huang IT; Dhungel B; Shrestha R; Bridle KR; Crawford DHG; Jayachandran A; Steel JC
Expert Opin Investig Drugs; 2019 Jan; 28(1):7-18. PubMed ID: 30474444
[TBL] [Abstract][Full Text] [Related]
18. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
[TBL] [Abstract][Full Text] [Related]
19. Peptidyl-Prolyl cis/trans Isomerase NIMA-Interacting 1 as a Therapeutic Target in Hepatocellular Carcinoma.
Kim G; Kim JY; Choi HS
Biol Pharm Bull; 2015; 38(7):975-9. PubMed ID: 26133706
[TBL] [Abstract][Full Text] [Related]
20. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells.
Lee KY; Lee JW; Nam HJ; Shim JH; Song Y; Kang KW
Mol Cells; 2011 Jul; 32(1):107-11. PubMed ID: 21573702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
